125 related articles for article (PubMed ID: 12176784)
1. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Bajetta E; Martinetti A; Zilembo N; Pozzi P; La Torre I; Ferrari L; Seregni E; Longarini R; Salvucci G; Bombardieri E
Ann Oncol; 2002 Jul; 13(7):1059-66. PubMed ID: 12176784
[TBL] [Abstract][Full Text] [Related]
2. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.
Leder BZ; Finkelstein JS
Osteoporos Int; 2005 Dec; 16(12):1487-94. PubMed ID: 15856361
[TBL] [Abstract][Full Text] [Related]
3. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
4. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
5. The effect of short-term treatment with micronized estradiol on bone turnover and gonadotrophins in older men.
Taxel P; Kennedy D; Fall P; Willard A; Shoukri K; Clive J; Raisz LG
Endocr Res; 2000 Aug; 26(3):381-98. PubMed ID: 11019903
[TBL] [Abstract][Full Text] [Related]
6. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
8. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Geisler J; Detre S; Berntsen H; Ottestad L; Lindtjørn B; Dowsett M; Einstein Lønning P
Clin Cancer Res; 2001 May; 7(5):1230-6. PubMed ID: 11350888
[TBL] [Abstract][Full Text] [Related]
9. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
[TBL] [Abstract][Full Text] [Related]
10. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
12. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
13. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Anan K; Mitsuyama S; Yanagita Y; Kimura M; Doihara H; Komaki K; Kusama M; Ikeda T
Breast Cancer Res Treat; 2011 Aug; 128(3):775-81. PubMed ID: 21638048
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
15. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
16. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
Bunck MC; Toorians AW; Lips P; Gooren LJ
Eur J Endocrinol; 2006 Apr; 154(4):569-75. PubMed ID: 16556720
[TBL] [Abstract][Full Text] [Related]
17. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Bonanni B; Serrano D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Macis D; Cazzaniga M; Luini A; Cassano E; Oldani S; Lien EA; Pelosi G; Decensi A
Clin Cancer Res; 2009 Nov; 15(22):7053-60. PubMed ID: 19887477
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of androgens and estrogens on bone turnover in normal men.
Leder BZ; LeBlanc KM; Schoenfeld DA; Eastell R; Finkelstein JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):204-10. PubMed ID: 12519853
[TBL] [Abstract][Full Text] [Related]
20. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
Ferrari L; Bajetta E; Martinetti A; Celio L; Longarini R; La Torre I; Buzzoni R; Gattinoni L; Seregni E; Bombardieri E
Int J Oncol; 2003 May; 22(5):1081-9. PubMed ID: 12684675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]